Reinventing Meniscus Treatments

The meniscus plays a critical role in the knee, including stability of the joint and shock absorbing protection. We know from scientific evidence, as well as our team’s first-hand clinical experience, that meniscus injuries present a major treatment challenge. Since the meniscus has limited healing ability, the current standard of care for those with ongoing symptoms is to cut out the damaged portion of the tissue (a meniscectomy). The loss of the meniscus cushion can lead to chronic pain, impaired mobility, and the early onset of arthritis over time. OrthoPreserve’s meniscus implant is intended to replace a dysfunctional meniscus to relieve symptoms and reduce the risks of accelerated joint degeneration that would normally accompany a meniscectomy.

2021: OrthoPreserve was founded by a team of orthopedic clinicians and biomedical engineers focused on bringing a new treatment to the patients in need: a meniscus replacement.

2023: OrthoPreserve was awarded a National Institutes of Health (NIH) SBIR grant for continued pre-clinical development of the implant.

2024: OrthoPreserve was granted Breakthrough Device Designation from the FDA, highlighting the implant’s potential to provide a superior treatment to existing options and accelerating its regulatory timeline.

Ultimately, our mission is to help patients return to pain-free activity, restore their quality of life, and potentially delay arthritis and the need for a total knee replacement with a far less invasive alternative - OrthoPreserve’s meniscus implant.